|
Vol. 5, No. 086 |
|
Underwriter: |
|
|
|
Resources: |
.gif) |
Desperately Seeking Cures
In This Issue:
LEAD
WHAT'S NEW AT ZERO
- Memorial Day Weekend Special: Registration fee is waived if you sign up by June 1 for ZERO’s Summit to End Prostate Cancer
- Increased Funding Sought for Prostate
Cancer Research - Let Congress Know Your Concerns
- Join ZERO's DASH FOR DAD Endurance Team at the Marine Corps Marathon on Sunday, Oct. 31
- 'DASH FOR DAD' Race Series Coming to 12 Cities to Raise Prostate Cancer Awareness
RESEARCH AND TREATMENT UPDATE
- Gene Fusions May Be the 'Smoking Gun' in Prostate Cancer Development, U-M Study Finds
- Signaling Protein Spurs Spread of Prostate Cancer, Scientists Find
- Tasquinimod in Treatment of Patients with Metastatic CRPC
- Prostate Volume and Risk for Acute GU Side Effects After IMRT
- Shrew Spit Tames Cancer Cells
|
[Advertisement]
|
Lead
Desperately Seeking Cures
Frustration is growing with how few seemingly promising scientific discoveries lead to something to actually help patients, especially in what is thought to be a “golden age of genetics, neuroscience, and biomedical research,” this article indicates.
The Cancer Preventers Many Don't Know About, or Want
Chemo prevention was expected to be a “public-health revolution, saving many lives,” yet few people are taking advantage of the drugs – two for the prostate gland and two for the breast – because they reduce but don’t eliminate the risk of cancer and can have dangerous side effects.
|
[Advertisement]
|
What's New at ZERO
Memorial Day Weekend Special: Registration fee is waived if you sign up by June 1 for ZERO’s Summit to End Prostate Cancer
This 2010 Summit to End Prostate Cancer, set for September 14-16 in Washington, D.C., will focus on effective strategies for increasing the Federal investment in prostate cancer research.
During the Summit, participants will have the opportunity to meet with their elected officials on Capitol Hill and learn more about the federal legislative process.
Increased Funding Sought for Prostate Cancer Research
Dr. Jonathan Simons
and Sherry Galloway testified for increased prostate cancer research funding.
(photo credit: Marianne Manilov)
The Appropriations Defense subcommittee of the U.S. House of Representatives heard testimony May 20 on the need for increased funding for the Prostate Cancer Research Program (PCRP), part of the Congressionally Directed Medical Research Program (CDMRP).
PCRP funding has remained flat at $80 million each year for almost a decade, and supporters are seeking an increase to $125 million annually so critical research can move forward to help find a cure for prostate cancer.
Sherry Galloway, a Registered Nurse by profession and a newly-elected ZERO board member, was among five witnesses who advocated for increased funding. Mrs. Galloway shared her personal experiences with prostate cancer, as her husband is a prostate cancer survivor and her 36 year old son, Jeremy, died from an aggressive form of prostate cancer after an 18-month struggle.
Also testifying before the subcommittee was Dr. Jonathan W. Simons, CEO and president of the Prostate Cancer Foundation, who focused on the scientific needs of the prostate cancer community.
Both speakers were well received by the seven members of the subcommittee in attendance. At times, members were moved to tears during Sherry’s testimony. After the conclusion of the hearing, one subcommittee member told Sherry that her testimony “made a difference.”
To view Mrs. Galloway's prepared testimony, click here.- To view Dr. Simons' prepared testimony, click here.
Let Congress Know Your Concerns
We encourage you to contact your elected representatives on Capitol Hill to indicate your support for early detection, men's prostate health and the need for research funding to improve early diagnosis of prostate cancer.
Join ZERO's DASH FOR DAD Endurance Team at the Marine Corps Marathon on Sunday Oct. 31
Be a pioneer. Be a fighter. Be a winner. Help end prostate cancer!
The renowned Marine Corps Marathon in Washington, D.C. begins and ends at the world-famous Marine Corps War Memorial, passing the Lincoln, Jefferson and Washington memorials along the race route.
"The People's Marathon" attracts runners from all over the world – young and old, first-time marathoners and veterans – who compete in this endurance race for their own personal goals.
Now you can join the fight to end prostate cancer.
All participants receive guaranteed entry into the race, a technical training shirt, fundraising website and advice, and a pre-race dinner. Please commit to raise a minimum of $1,000 to help ZERO end prostate cancer. Participants who are traveling to Washington, D.C. for the event and raise $2,000 will receive a $500 travel reimbursement.
Click here for more information and sign up today!
Other ZERO DASH FOR DAD Endurance Teams:
'DASH FOR DAD' Race Series Coming to 12 Cities to Raise Prostate Cancer Awareness
As National Race Series Expands Across U.S. in 2010, Supporters Are Encouraged to Bring This Event to Their City
Lace up your sneakers and join us in the race to end prostate cancer!
DASH FOR DAD, the premier prostate cancer race series in the U.S., is a heartfelt tight-knit community event that brings together athletes, cancer survivors, physicians, caregivers, family members and friends. Proceeds from each 10K race are used to provide free prostate cancer testing for men in the local community of the event.
ZERO – The Project to End Prostate Cancer, with sponsors from across the country, has grown the DASH FOR DAD and its partner races – the Great Prostate Cancer Challenge® – to include 12 cities and an expected 6,000 runners competing in 2010.
The DASH FOR DAD or partnering Great Prostate Cancer Challenge® 5K will be held in the following cities:
- Albuquerque, NM - Nov. 2010
- Baltimore, MD - Sept. 26
- Buffalo, NY - Sept. 19
- Central FL - Oct. 23
- Columbus, OH - Aug. 29
- Harrisburg, PA - Sept. 10
- Indianapolis, IN - Sept. 18
- Kansas City, MO - Sept. 19
- Memphis, TN - Sept. 11
- Nashville, TN - Sept. 11
- New York, NY (Long Island) - Nov. 14
- Washington, DC (Alexandria, VA) - Sept. 26
Since the national race series began in 2008, more than $1 million has been raised to promote prostate cancer awareness, early detection and research. Many runners create teams and collect monetary pledges from family and friends to boost funding for local prostate cancer services.
Urology medical practices and other supporting organizations are especially encouraged to organize a DASH FOR DAD, due to the importance of providing free prostate cancer testing and promoting research for a cure. Click here to download the DASH FOR DAD race application.
"DASH FOR DAD elevates prostate cancer awareness to a broader nationwide level," said ZERO's CEO Skip Lockwood. "We all know someone who is impacted by this most commonly diagnosed cancer among men, striking one in every six. That's why we must do all that we can to put an end to this horrible disease."
For more information about the DASH FOR DAD 10K or if you're interested in hosting a DASH FOR DAD run to your city, contact Tracy Cesaretti.
|
[Advertisement]
|
Research and Treatment Update
Gene Fusions May Be the 'Smoking Gun' in Prostate
Cancer Development, U-M Study Finds
Gene fusion – not the androgen receptor – is a more specific “bad actor” in prostate cancer and should be the focus of treatment, this research shows.
Signaling Protein Spurs Spread of Prostate Cancer,
Scientists Find
Stat5, a signaling protein previously found to be key to survival of prostate cancer, also could be one of the primary players that causes prostate cancer to spread, according to this research.
Tasquinimod in Treatment of Patients with Metastatic CRPC
Tasquinimod, an orally administered investigational drug, is shown to have positive results in this study of patients with metastatic, castration-resistant prostate cancer.
Prostate Volume and Risk for Acute GU Side Effects After IMRT
This research suggests a direct correlation between genitourinary problems and prostate cancer patients with large prostates, following their treatment with IMRT (intensity-modulated radiation therapy).
Shrew Spit Tames Cancer Cells
The venomous saliva of this mouse-like mammal contains the chemical soricidin that has shown an anti-cancer effect against prostate and breast tumors in animal studies by blocking calcium from going to the cancer cells, this study shows.
PSA Standardization DVD: